On 13 April 2016, we announced that we had closed enrolment into our Phase 2B placebo controlled efficacy trial of MIS416 in patients with SPMS. With this significant clinical development milestone achieved, we can now advise that the Phase 2B study should be completed in April next year and that a substantive initial clinical trial report should be released about four months later.
To view Report please download PDF attached:
Download this document
